GET DAILY SIGNALSCDT Equity (CDT) Stock Plunges -93% in 30 Days Due to Massive Dilution
Key Takeaways
- CDT shares fell roughly 93% over the trailing 30 days, sliding from about $0.99 at the start of October to about $0.07 by early November.
- The move extends a far deeper collapse: the stock traded near $71 in early August, leaving the three-month decline near 99.9%.
- Severe share dilution was the central driver, after pre-funded warrants covering roughly 12.1 million shares were exercised in late August 2026.
- CDT reports no product revenue and has flagged substantial doubt about its ability to continue as a going concern.
- A series of reverse stock splits has been used to maintain Nasdaq listing compliance as the share price deteriorated.
- For additional details, explore CDT's Price Targets, Earnings, and Forecast pages.
- Discover top-performing automated strategies on the Trending AI Robots page.
Company Background for CDT Equity (CDT)
CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., is a data-driven biopharmaceutical company based in Naples, Florida. It focuses on identifying, enhancing, and monetizing therapeutic assets, using artificial intelligence, solid-form chemistry and co-crystallization, and asset repositioning rather than running late-stage clinical trials itself. Its pipeline, licensed from AstraZeneca, includes AZD1656 (a glucokinase activator in Phase II for autoimmune disorders), AZD5658 (Phase I for Type 2 diabetes), and AZD5904 (completed Phase I for idiopathic male infertility), alongside earlier programs in dermatology and animal health. Investors follow CDT largely for its repositioning strategy and its push into AI-driven drug discovery through its stake in Sarborg Limited, a private "agentic AI" venture. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Performance: 30 Days and the Quarterly Picture
Over the last 30 days, CDT fell roughly 93%, from a closing price near $0.99 in early October to about $0.07 by early November. The decline has been persistent rather than a single-event gap, with the stock losing ground through much of the month amid heavy trading volume.
The quarterly picture is even starker. In early August, CDT traded near $71; the subsequent three-month move represents a decline of roughly 99.9%. The collapse accelerated in September, when a "capital update" and the full effect of a large warrant exercise became apparent to the market.
What Drove the 30-Day Decline
The most important factor has been dilution. In July 2026, CDT agreed to issue pre-funded warrants covering approximately 12.13 million shares at a nominal exercise price of $0.0001 to acquire a stake in Sarborg Limited. When holders exercised those warrants on a cashless basis in late August, the company issued roughly 12.13 million new common shares — close to nine of every ten shares then outstanding. The resulting overhang and continued selling pressure weighed heavily on the stock through October.
Fundamental concerns compounded the move. CDT generates no product revenue and has disclosed substantial doubt about its ability to continue as a going concern, while reporting steady net losses. Against that backdrop, the stock's drift toward penny-stock levels reflected waning confidence in the company's ability to convert its illiquid Sarborg stake and pipeline into tangible value. From what I see, this dilution event was the clear catalyst.
Factors Behind the Quarterly Collapse
The quarterly collapse traces back to the company's September "capital update," which framed a large share issuance as reassuring news while markets read it as dilution. Shares fell in the regular session and dropped further after hours as investors digested the scale of the new share count. The company has also used a series of reverse stock splits — including a 1-for-10 reverse split effective in July 2026 — to prop up the share price and maintain Nasdaq listing compliance, a pattern that itself signals ongoing stress. Combined with no product revenue and going-concern disclosures, these factors produced the extended decline.
What to Watch Next for CDT Equity (CDT)
Several factors will shape CDT's path. First, watch any additional capital raises or share issuances, including use of the company's at-the-market offering program, which could further dilute existing holders. Second, monitor whether the Sarborg Limited stake is converted into tangible value or remains an illiquid mark on the balance sheet. Third, track the progression of the AZD1656, AZD5658, and AZD5904 programs and any licensing or partnership agreements, including the recent evaluation agreement with Manoira in animal health. Finally, watch Nasdaq listing compliance and the company's ability to resolve its going-concern disclosure. I’m watching this closely as these elements unfold. None of this constitutes financial advice.
Using Tickeron’s Trending AI Robots for Perspective
In my research process, I often review Tickeron’s Trending AI Robots to compare how different automated strategies have handled volatile names like this one. The page highlights top-performing bots across strategies and timeframes, giving a useful way to benchmark approaches without relying on a single signal.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
CDT in -18.07% downward trend, sliding for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CDT declined for three days, in 281 of 292 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for CDT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.001) is normal, around the industry mean (3.104). P/E Ratio (-0.000) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. CDT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement